CHU de Nantes
Nantes, 44093, France
Location status: Recruiting
NCT Number: NCT06285292
Stress urinary incontinence (SUI) affects around 40% of women and has a major impact on quality of life. The gold standard for the treatment of SUI is pelvicfloor rehabilitation, but this presents constraints in terms of availability of healthcare professionals, as well as organization and travel for patients. Innovative devices offer self-training exercises for the pelvicfloor, thus promoting motivation and adherence to treatment. The hypothesis of this study is to prove that the use of a pelvicfloor medical device combined with 2 rehabilitation sessions is not inferior to pelvic-perineal rehabilitation.
Interested in participating?
Request Info18 year–60 year
Female
Interventional
Not applicable
Nantes, 44093, France
Location status: Recruiting
Two groups will be studied:
Recruitment will be carried out with the help of healthcare professionals. The investigators involved in the study will be physiotherapists specializing in pelvic-perineal rehabilitation.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients in the "intervention" group (rehabilitation with the EMY medical device) will undergo 2 rehabilitation sessions with a physiotherapist trained in pelviperineology between M0 and M2. The aim of these sessions will be to learn proper perineal contraction and combat the deficits identified during the physiotherapist's assessment. They will have to perform pelvic-perineal re-education exercises with the EMY device on 3 different days a week, for 15 minutes, over a period of 3 months. Then, for a further 3 months, their program can be modified for free, on-demand use (e.g. 2 x 10 minutes per week). After the main criterion at M6, they will be free to modify their rehabilitation program in the application according to their symptoms, and follow their program until the end of the study
Other names: pelvic-perineal probe
Time frame: 6 months
The non-inferiority of 2 sessions of pelvic floor rehabilitation associated with the use of the EMY medical device compared with 15 sessions of pelvic floor rehabilitation (gold standard) on the urinary symptoms score at 6 months will be assessed using the ICIQ-UI SF questionnaire.
Time frame: 0 month, 1 month, 3 months, 6 months, 12 months
changes in quality of life will be studied using the validated I - QoL questionnaire
Time frame: 0 month, 1 month, 3 months, 12 months
changes in urinary symptoms will be studied using the validated ICIQ-UI SF questionnaire
Time frame: 0 month, 1 month, 3 months, 6 months, 12 months
The cost/utility ratio will be studied using the cost/QALY ratio. The costs will relate to the consumption of reimbursed or non-reimbursed care (medical and paramedical consultations, hospitalization, drug treatment, absorbent pads, pessaries, etc.). QALYs will be estimated on the basis of responses to the validated EQ-5D 5L questionnaire.
Time frame: 1 month, 3 months, 6 months, 12 months
the qualitative component will consist of questionnaires evaluating :
Contact information is provided by the study sponsor or research team.
Selma EL ANDALOUSSI, manager
CONTACT
Thibault THUBERT, PHD
CONTACT
Nantes University Hospital
Other
Acronym: PRIME
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07692789
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Columbus, Ohio, United States
View Trial DetailsNCT06094543
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Redwood City, California, United States
View Trial DetailsNCT05719220
BPH, Female Urogenital Diseases
San Francisco, California, United States
View Trial DetailsNCT07555548
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Doncaster, United Kingdom
View Trial Details